معرفی
Dr. Kaitlin Mayne is a Clinical Lecturer in Renal Medicine at the School of Cardiovascular & Metabolic Health, University of Glasgow. Her research focuses on chronic kidney disease (CKD), cardiovascular complications, and the effects of pharmacological agents like empagliflozin and vicadrostat. She leads analyses in major trials such as EMPA-KIDNEY and EASi-KIDNEY, exploring drug efficacy in CKD populations. Her work spans fluid management, biomarker discovery, and guideline-informed clinical practices. Notably, she investigates post-COVID-19 multisystem syndromes and socioeconomic disparities in healthcare outcomes. Dr. Mayne collaborates widely, contributing to high-impact journals in nephrology and cardiology.
Research interests include SGLT2 inhibitors’ role in CKD progression, bioimpedance technologies, and frailty in renal patients. Her recent studies highlight empagliflozin’s benefits in reducing uric acid levels and cardiovascular risks, alongside exploring aldosterone synthase inhibitors for cardio-renal protection. She also examines sex/gender differences in CKD management and hemodialysis outcomes through inflammatory biomarkers.
In 2025–2023, her articles emphasize drug mechanisms, subgroup analyses (e.g., Japanese CKD patients), and long-term trial results. Collaborations with groups like the EMPA-KIDNEY Collaborative Group underscore her role in large-scale clinical research. While no awards are listed, her prolific peer-reviewed output reflects her academic standing.
Dr. Mayne’s advising and grants are not detailed here, but her publications suggest involvement in collaborative grants supporting CKD and post-COVID research. She contributes to interdisciplinary teams, such as those investigating renal MRI advancements and post-infectious illness trajectories.
